Compare · UFPT vs WST
UFPT vs WST
Side-by-side comparison of UFP Technologies Inc. (UFPT) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both UFPT and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.52B, about 10.4x UFPT ($2.36B).
- UFPT has been more active in the news (12 items in the past 4 weeks vs 1 for WST).
- WST has more recent analyst coverage (18 ratings vs 7 for UFPT).
- Company
- UFP Technologies Inc.
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $2.36B
- $24.52B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 1993
- News (4w)
- 12
- 1
- Recent ratings
- 7
- 18
UFP Technologies Inc.
UFP Technologies, Inc. designs and converts foams, films, and plastics materials for the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets in the United States. It offers single patient use surfaces, advanced wound care, infection prevention, and disposables for surgical procedures, endoscopic procedures, orthopedic implants, orthopedic appliances, biopharma drug manufacturing, etc.; molded components for automotive, aerospace, and defense markets; recycled protective packaging for B2C brands; and reusable cases and custom inserts. The company markets and sells its products through direct sales forces and independent manufacturer representatives. UFP Technologies, Inc. was founded in 1963 and is headquartered in Newburyport, Massachusetts.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest UFPT
- UFP Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the 17th Annual Midwest IDEAS Investor Conference on August 26th in Chicago, IL
- Director Hudson Symeria sold $95,095 worth of shares (298 units at $319.11), decreasing direct ownership by 24% to 927 units (SEC Form 4)
- Director Hudson Symeria sold $625,141 worth of shares (1,926 units at $324.58) and exercised 1,196 shares at a strike of $206.29, decreasing direct ownership by 37% to 1,225 units (SEC Form 4)
- Director Feldmann Cynthia L sold $324,260 worth of shares (1,000 units at $324.26), decreasing direct ownership by 18% to 4,476 units (SEC Form 4)
- Amendment: SEC Form 4 filed by Director Hassett Joseph John
- Executive Chairman Bailly R Jeffrey sold $4,113,221 worth of shares (13,011 units at $316.13) (SEC Form 4)
- Executive Chairman Bailly R Jeffrey sold $4,997,051 worth of shares (15,695 units at $318.38) (SEC Form 4)
- Vice President Holt Jason sold $348,700 worth of shares (1,100 units at $317.00), decreasing direct ownership by 12% to 7,878 units (SEC Form 4)
- SEC Form 10-Q filed by UFP Technologies Inc.
Latest WST
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target